RIVAROXABAN TARO 2.5 MG

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

RIVAROXABAN

متاح من:

TARO PHARMACEUTICAL INDUSTRIES LTD

ATC رمز:

B01AX06

الشكل الصيدلاني:

FILM COATED TABLETS

تركيب:

RIVAROXABAN 2.5 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

TARO PHARMACEUTICAL INDUSTRIES LTD

المجال العلاجي:

RIVAROXABAN

الخصائص العلاجية:

RIVAROXABAN TARO, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel , is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. RIVAROXABAN TARO, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.

تاريخ الترخيص:

2023-01-05

نشرة المعلومات

SAFETY INFORMATION CARD FOR PATIENTS
UNDER ANTICOAGULANT TREATMENT WITH RIVAROXABAN TARO
RIVAROXABAN TARO 2.5 MG
RIVAROXABAN TARO 10 MG
RIVAROXABAN TARO 15 MG
RIVAROXABAN TARO 20 MG
Keep this card with you at all times
Present this card to every doctor or dentist
at the beginning of the visit
THE PATIENT CARRYING THIS CARD IS UNDER ANTICOAGULANT TREATMENT
WITH RIVAROXABAN TARO
Name _________________________________________________
Address _______________________________________________
Date of birth ___________________ Weight ___________________
Information regarding concomitant diseases and medications
_____________________________
INFORMATION IN CASE OF EMERGENCY
IN CASE OF EMERGENCY, PLEASE INFORM THE TREATING DOCTOR
______________________
Telephone ______________________________________________
PLEASE ALSO NOTIFY:
Name _____________________Relationship ______________
Telephone ______________________________________________
Emergency phone (clinic/first aid) _________________________
INFORMATION REGARDING USE OF THE MEDICINE
Treatment start date __________________________________
Indication ___________________________________________
Dosage and administration regimen ______________________
Renal function at treatment onset (creatinine clearance mL/min)
___________________________________________________
INFORMATION FOR HEALTHCARE PROVIDERS:
Measuring INR is not suitable for assessment of the anticoagulant
activity of Rivaroxaban Taro and should therefore not be used for this
purpose.
INFORMATION ON ANTICOAGULANTS AND GUIDANCE FOR THE PATIENT

The anticoagulant, Rivaroxaban Taro, is a blood thinner, which
protects you from the development of dangerous blood clots.

Rivaroxaban Taro must be taken exactly as prescribed by your
doctor. To ensure optimal protection from blood clots, you
should strictly comply with the administration schedule as
recommended by your doctor and do not skip any dose,
unless instructed by your doctor.

Do not stop taking Rivaroxaban Taro without consulting your
doctor, as your